Mind Medicine (MindMed) Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
MNMD Nasdaq 8731 https://mindmed.co/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Mind Medicine (MindMed) Inc

MindMed to Present at Upcoming May Medical Conferences - Apr 25th, 2024 11:00 am
MindMed to Present at Upcoming April Medical Conferences - Apr 2nd, 2024 11:00 am
MindMed Announces Voluntary Delisting from Cboe Canada - Apr 1st, 2024 9:00 pm
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference - Mar 11th, 2024 11:00 am
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Mar 10th, 2024 3:10 pm
Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement - Mar 7th, 2024 12:13 pm
MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder - Mar 7th, 2024 11:00 am
MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120 - Mar 1st, 2024 2:00 pm
MindMed Reports 2023 Financial Results and Business Updates - Feb 28th, 2024 12:05 pm
MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update - Feb 22nd, 2024 12:00 pm
MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference - Feb 7th, 2024 12:00 pm
MindMed Announces Business Update and Anticipated Milestones for 2024 - Jan 8th, 2024 12:45 pm
MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder - Dec 14th, 2023 12:30 pm
MindMed Reports Third Quarter 2023 Financial Results and Business Highlights - Nov 2nd, 2023 8:01 pm
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business Update - Oct 26th, 2023 11:30 am
MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD) - Oct 24th, 2023 11:30 am
MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress - Oct 3rd, 2023 11:30 am
MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry Summit - Sep 14th, 2023 11:30 am
MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD) - Sep 12th, 2023 11:30 am
MindMed to Participate at September Investor Conferences - Aug 28th, 2023 11:30 am